Síndrome mielodisplásica
Summary
Definition
History and exam
Key diagnostic factors
- idade avançada
- fadiga
- intolerância ao exercício
- palidez
- hematomas ou sangramentos
- quimioterapia e/ou radioterapia prévias
- doença congênita
- infecções bacterianas
Other diagnostic factors
- presença de fatores de risco
- doenças autoimunes
- esplenomegalia
- hepatomegalia
- linfadenopatia
Risk factors
- idade >70 anos
- quimioterapia prévia
- radioterapia anterior
- transplante autólogo de células-tronco hematopoiéticas prévio
- doenças congênitas
- exposição ao tabaco
- exposição ao benzeno
- anemia aplásica
- hemoglobinúria paroxística noturna (HPN)
Diagnostic tests
1st tests to order
- Hemograma completo com diferencial
- esfregaço de sangue periférico
- contagem de reticulócitos
- folato eritrocitário
- vitamina B12 sérica
- perfil de ferro
- aspiração da medula óssea com coloração para ferro
- punção por agulha grossa (core biopsy) da medula óssea
- teste genético
Tests to consider
- sorologia viral
- eritropoetina sérica
- lactato desidrogenase
- tipagem HLA (antígeno leucocitário humano)
- citometria de fluxo
Treatment algorithm
doença de baixo risco: assintomático
doença de baixo risco: SMD-5q (del(5q) ± uma outra anormalidade citogenética, exceto aquelas que envolvem o cromossomo 7) com anemia sintomática
doença de baixo risco: SMD-SF3B1 (sem del(5q) ± outras anormalidades citogenéticas com sideroblastos em anel ≥15% [ou ≥5% com mutação SF3B1]) com anemia sintomática
doença de baixo risco: sem del(5q) com sideroblastos em anel <15% (ou <5% com mutação SF3B1) com anemia sintomática
doença de baixo risco: com trombocitopenia ou neutropenia clinicamente relevante (sem anemia sintomática)
doença de alto risco: candidato a transplante
doença de alto risco: não candidato a transplante
Contributors
Authors
Vijaya Raj Bhatt, MBBS, MS
Professor
Section Leader, Malignant Hematology
University of Nebraska Medical Center Division of Hematology-Oncology
Nebraska
NE
Disclosures
VRB has participated in a Safety Monitoring Committee for Protagonist Therapeutics and has served as an Associate Editor for the journal Current Problems in Cancer, and as a member of the National Comprehensive Cancer Network Acute Myeloid Leukemia panel. He has received consulting fees from Taiho, Sanofi, Imugene, Genentech, Incyte, Servier Pharmaceuticals, and AbbVie; research funding (institutional) from Cynata Therapeutics, MEI Pharma, Actinium Pharmaceutical, Sanofi, AbbVie, Pfizer, Incyte, Jazz, and NMDP; and drug support (institutional) from Chimerix for a trial.
Prajwal Dhakal, MBBS
Clinical Assistant Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation
University of Iowa
Iowa City
IA
Disclosures
PD has received honoraria from the Aplastic Anemia and MDS International Foundation, and Iowa Oncology Society. PD has received consulting fees from AbbVie, Genentech, and Stemline Therapeutics.
Acknowledgements
Dr Vijaya Raj Bhatt and Dr Prajwal Dhakal would like to gratefully acknowledge Professor Apar Kishor Ganti and Associate Professor Alissa Marr, previous contributors to this topic.
Disclosures
AKG has received research support from Amgen, Apexigen, Bristol-Myers Squibb, Janssen, Merck, New Link Genetics, Pfizer, and Takeda Oncology. AKG has been reimbursed for consulting work for AbbVie and Genentech. None of the grants or payments relate to work involving myelodysplastic syndrome. AM declares that she has no competing interests.
Peer reviewers
David P. Steensma, MD, FACP
Associate Professor of Medicine (Hematology) and Oncology
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester
MN
Disclosures
DPS declares that he has no competing interests.
Adrian C. Newland, BA, MB, BCh, MA, FRCP, FRCPath
Professor of Haematology
Queen Mary University
London
UK
Disclosures
ACN declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Killick SB, Wiseman DH, Quek L, et al. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of adult myelodysplastic syndromes. Br J Haematol. 2021 Jul;194(2):282-93.Full text Abstract
Killick SB, Ingram W, Culligan D, et al. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. Br J Haematol. 2021 Jul;194(2):267-81.Full text Abstract
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes [internet publication].Full text
Fenaux P, Haase D, Santini V, et al; ESMO Guidelines Committee. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Feb;32(2):142-56.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Anemia aplásica
- Infecção pelo vírus da imunodeficiência humana (HIV)
- Outras infecções virais (por exemplo, parvovírus, CMV ou hepatite)
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: myelodysplastic syndromes
- Guidelines for the diagnosis and treatment of myelodysplastic neoplasias and chronic myelomonocytic leukemia (11th update)
More GuidelinesCalculators
International Prognostic Scoring System revisado (IPSS-R) para síndrome mielodisplásica
More Calculators
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer